Terns Pharmaceuticals, Inc. (TERN)
Largest Insider Buys in Sector
TERN Stock Price History Chart
TERN Stock Performance
About Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Insider Activity of Terns Pharmaceuticals, Inc.
Over the last 12 months, insiders at Terns Pharmaceuticals, Inc. have bought $48,161 and sold $2.8M worth of Terns Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Terns Pharmaceuticals, Inc. have bought $14.15M and sold $5.52M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Vignola Mark J. (Chief Financial Officer) — $24,081. Yoon Seokho Bryan (COO and General Counsel) — $24,081.
The last purchase of 4,791 shares for transaction amount of $21,272 was made by Yoon Seokho Bryan (COO and General Counsel) on 2024‑05‑31.
List of Insider Buy and Sell Transactions, Terns Pharmaceuticals, Inc.
| 2024-05-31 | Yoon Seokho Bryan | COO and General Counsel | 4,791 0.0055% | $4.44 | $21,272 | +20.88% | ||
| 2024-05-31 | Vignola Mark J. | Chief Financial Officer | 4,791 0.0055% | $4.44 | $21,272 | +20.88% | ||
| 2024-04-03 | Sale | Vivo Opportunity, LLC | 10 percent owner | 138,066 0.2207% | $6.20 | $856,009 | -1.83% | |
| 2024-04-02 | Sale | Vivo Opportunity, LLC | 10 percent owner | 101,480 0.1572% | $6.65 | $674,842 | -11.07% | |
| 2024-04-01 | Sale | Vivo Opportunity, LLC | 10 percent owner | 181,117 0.2758% | $6.99 | $1.27M | -16.76% | |
| 2023-11-30 | Yoon Seokho Bryan | COO and General Counsel | 743 0.001% | $3.78 | $2,809 | +42.66% | ||
| 2023-11-30 | Vignola Mark J. | Chief Financial Officer | 743 0.001% | $3.78 | $2,809 | +42.66% | ||
| 2023-05-31 | Yoon Seokho Bryan | COO and General Counsel | 9,997 0.0019% | $1.41 | $14,096 | -43.54% | ||
| 2023-05-31 | Vignola Mark J. | Chief Financial Officer | 9,997 0.0019% | $1.41 | $14,096 | -43.54% | ||
| 2023-05-31 | Sundaram Senthil Vel | Chief Executive Officer | 2,111 0.0004% | $1.41 | $2,977 | -43.54% | ||
| 2022-12-23 | ORBIMED ADVISORS LLC | director | 137,931 0.2216% | $7.25 | $1,000,000 | +0.36% | ||
| 2022-12-23 | GORDON CARL L | director | 137,931 0.2216% | $7.25 | $1,000,000 | +0.36% | ||
| 2022-12-23 | Vivo Opportunity, LLC | director | 758,620 1.2188% | $7.25 | $5.5M | +0.36% | ||
| 2022-12-23 | Lu Hongbo | director | 758,620 1.2188% | $7.25 | $5.5M | +0.36% | ||
| 2022-11-30 | Yoon Seokho Bryan | 3 <0.0001% | $1.41 | $4 | +7.66% | |||
| 2022-11-30 | Vignola Mark J. | 3 <0.0001% | $1.41 | $4 | +7.66% | |||
| 2022-11-30 | Sundaram Senthil Vel | 3 <0.0001% | $1.41 | $4 | +7.66% | |||
| 2022-11-23 | Sale | LAV Biosciences Fund V, L.P. | director | 1.5M 2.6886% | $5.50 | $8.25M | +49.20% | |
| 2022-09-07 | Vivo Capital Surplus Fund VIII, L.P. | 600,000 1.476% | $3.60 | $2.16M | +120.13% | |||
| 2022-09-07 | Lu Hongbo | 600,000 1.476% | $3.60 | $2.16M | +120.13% |
Insider Historical Profitability
| Vivo Opportunity, LLC | director | 268573 7.0236% | $6.67 | 1 | 3 | +0.36% |
| Vignola Mark J. | Chief Financial Officer | 91940 0.0298% | $6.67 | 5 | 0 | +85.92% |
| Yoon Seokho Bryan | COO and General Counsel | 91940 0.0298% | $6.67 | 5 | 0 | +85.92% |
| GORDON CARL L | director | 4882854 7.9018% | $6.67 | 2 | 0 | <0.0001% |
| ORBIMED ADVISORS LLC | director | 4882854 7.9018% | $6.67 | 2 | 0 | <0.0001% |
| Lu Hongbo | director | 4340212 7.0236% | $6.67 | 2 | 0 | +60.25% |
| Vivo Capital Surplus Fund VIII, L.P. | 3581592 5.796% | $6.67 | 2 | 0 | +148.64% | |
| Flynn James E | 10 percent owner | 2382033 3.8548% | $6.67 | 1 | 0 | <0.0001% |
| Vivo Capital VIII, LLC | 10 percent owner | 2036557 3.2957% | $6.67 | 1 | 0 | <0.0001% |
| LAV Biosciences Fund V, L.P. | director | 405583 0.6563% | $6.67 | 0 | 1 | |
| Sundaram Senthil Vel | Chief Executive Officer | 9770 0.0158% | $6.67 | 3 | 0 | +85.92% |
Institutional Investor Ownership
| OrbiMed | $49.98M | 11.78 | 7.62M | 0% | +$0 | 1.02 | |
| Vivo Capital | $43.68M | 10.29 | 6.66M | 0% | +$0 | 3.85 | |
| Deep Track Capital Lp | $40.02M | 9.43 | 6.1M | 0% | +$0 | 0.18 | |
| Millennium Management LLC | $22.52M | 5.31 | 3.43M | +72.62% | +$9.47M | 0.02 | |
| Vr Adviser Llc | $22.37M | 5.27 | 3.41M | -24.17% | -$7.13M | 1.09 | |
| BlackRock | $21.75M | 5.13 | 3.32M | -2.74% | -$613,025.46 | <0.0001 | |
| Citadel Advisors LLC | $19.45M | 4.59 | 2.97M | +8,461.16% | +$19.23M | 0.01 | |
| Fidelity Investments | $18.12M | 4.27 | 2.76M | -7.63% | -$1.5M | <0.01 | |
| Franklin Templeton Investments | $15.63M | 3.68 | 2.38M | +3.21% | +$485,846.70 | 0.01 | |
| Point72 Asset Management | $14.57M | 3.43 | 2.22M | New | +$14.57M | 0.03 | |
| The Vanguard Group | $14.43M | 3.4 | 2.2M | +0.53% | +$75,669.60 | <0.0001 | |
| Fairmount Funds Management LLC | $13.38M | 3.15 | 2.04M | 0% | +$0 | 1.46 | |
| Janus Henderson | $13.13M | 3.1 | 2M | +40.6% | +$3.79M | 0.01 | |
| Suvretta Capital Management, LLC | $8.95M | 2.11 | 1.36M | -76.64% | -$29.35M | 0.38 | |
| Great Point Partners | $8.59M | 2.03 | 1.31M | 0% | +$0 | 1.44 | |
| Schonfeld Group | $7.84M | 1.85 | 1.2M | +193.19% | +$5.17M | 0.06 | |
| Driehaus Capital Management LLC | $7.11M | 1.68 | 1.08M | -4.08% | -$302,724.33 | 0.07 | |
| State Street | $5.94M | 1.4 | 905,494 | +2.1% | +$122,114.41 | <0.0001 | |
| Geode Capital Management | $5.68M | 1.34 | 865,921 | +3.03% | +$167,052.93 | <0.01 | |
| Adage Capital Partners Gp L L C | $5.58M | 1.31 | 850,000 | -19.05% | -$1.31M | 0.01 | |
| Russell Investments Group Ltd | $4.15M | 0.98 | 632,965 | +127.9% | +$2.33M | 0.01 | |
| Octagon Capital Advisors LP | $4.1M | 0.97 | 625,000 | New | +$4.1M | 0.54 | |
| Morgan Stanley | $3.85M | 0.91 | 586,793 | -65.98% | -$7.46M | <0.0001 | |
| ACUTA CAPITAL PARTNERS LLC | $3.05M | 0.72 | 465,079 | -16.24% | -$591,587.31 | 1.98 | |
| Affinity Asset Advisors | $2.95M | 0.7 | 450,000 | +581.82% | +$2.52M | 0.52 | |
| JPMorgan Chase | $2.77M | 0.65 | 421,637 | +93.23% | +$1.33M | <0.0001 | |
| Northern Trust | $2.33M | 0.55 | 355,796 | -0.76% | -$17,764.47 | <0.0001 | |
| Dimensional Fund Advisors | $2.23M | 0.53 | 340,017 | +336.9% | +$1.72M | <0.01 | |
| Monashee Investment Management LLC | $1.97M | 0.46 | 300,000 | New | +$1.97M | 0.17 | |
| Eversept Partners LP | $1.86M | 0.44 | 283,034 | New | +$1.86M | 0.14 | |
| Silverarc Capital Management Llc | $1.64M | 0.39 | 250,551 | -51.54% | -$1.75M | 0.48 | |
| Barclays | $1.63M | 0.38 | 248,304 | +193.57% | +$1.07M | <0.01 | |
| Bridger Management Llc | $1.62M | 0.38 | 246,800 | New | +$1.62M | 0.73 | |
| Goldman Sachs | $1.36M | 0.32 | 206,986 | +141.83% | +$796,351.69 | <0.0001 | |
| Samsara Biocapital Llc | $1.33M | 0.31 | 202,348 | 0% | +$0 | 0.21 | |
| Marshall Wace | $1.22M | 0.29 | 186,009 | New | +$1.22M | <0.01 | |
| Wellington Management Company | $1.13M | 0.27 | 172,599 | New | +$1.13M | <0.0001 | |
| Nuveen | $1.05M | 0.25 | 159,572 | +1.88% | +$19,286.41 | <0.0001 | |
| Citigroup | $1.03M | 0.24 | 157,561 | +2,121.05% | +$987,063.37 | <0.01 | |
| HighVista Strategies | $972,192.00 | 0.23 | 148,200 | 0% | +$0 | 0.36 | |
| Myda Advisors Llc | $918,400.00 | 0.22 | 140,000 | -1.67% | -$15,632.48 | 0.32 | |
| Charles Schwab | $751,835.00 | 0.18 | 114,609 | 0% | +$0 | <0.0001 | |
| BNY Mellon | $739,017.00 | 0.17 | 112,655 | -6.19% | -$48,740.81 | <0.0001 | |
| Ikarian Capital LLC | $580,540.00 | 0.14 | 88,497 | -46.52% | -$505,008.20 | 0.17 | |
| Prelude Capital | $555,101.00 | 0.13 | 84,619 | New | +$555,101.00 | 0.04 | |
| Hrt Financial Llc | $490,000.00 | 0.12 | 74,755 | New | +$490,000.00 | <0.01 | |
| Squarepoint Ops LLC | $468,128.00 | 0.11 | 71,361 | New | +$468,128.00 | <0.01 | |
| UBS | $411,764.00 | 0.1 | 62,769 | -42.13% | -$299,830.89 | <0.0001 | |
| Swiss National Bank | $400,160.00 | 0.09 | 61,000 | -10.16% | -$45,264.00 | <0.0001 | |
| RhumbLine Advisers | $386,911.00 | 0.09 | 58,982 | +2.46% | +$9,308.38 | <0.0001 |